Hirayama, Atsushi

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 315

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Schwartz, G. G., Szarek, M., Bittner, V. A., Diaz, R., Goodman, S. G., Jukema, J. W., Landmesser, U., López-Jaramillo, P., Manvelian, G., Pordy, R., et al. (2021) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 150

A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk

Kiyosue, A., Honarpour, N., Kurtz, C., Xue, A., Wasserman, S. M., & Hirayama, A. (2016) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 114

Highly Purified Eicosapentaenoic Acid May Increase Low-Density Lipoprotein Particle Size by Improving Triglyceride Metabolism in Patients With Hypertriglyceridemia

Tani, S., Nagao, K., Matsumoto, M., & Hirayama, A. (2013) · Circulation Journal

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 31

Anatomic and electrophysiologic differences between chronic and paroxysmal atrial flutter: intracardiac echocardiographic analysis

OHKUBO, K., WATANABE, I., OKUMURA, Y., ASHINO, S., KOFUNE, M., KAWAUCHI, K., YAMADA, T., KOFUNE, T., HASHIMOTO, K., SHINDO, A., et al. (2008) · Pacing and Clinical Electrophysiology

Cardiac Arrhythmias and TreatmentsCardiac electrophysiology and arrhythmias

Cited by 13